CARBYLAN THERAPEUTICS, INC. (NASDAQ:CBYL) Files An 8-K Submission of Matters to a Vote of Security Holders

CARBYLAN THERAPEUTICS, INC. (NASDAQ:CBYL) Files An 8-K Submission of Matters to a Vote of Security Holders

Story continues below

Item5.07.

Submission of Matters to a Vote of Security
Holders.

On November21, 2016, Carbylan Therapeutics, Inc. (the
Company) held a special meeting of its
stockholders at which the following items were voted on.

(1) Approval of the issuance of the Companys common stock to a
Share Purchase Agreement (the Share Purchase
Agreement
) entered into on June 15, 2016, by and
among the Company, KalVista Pharmaceuticals Ltd.
(Kalvista), the shareholders of KalVista and
the Seller Representative (as defined in the Share Purchase
Agreement).

Votes

Cast For

Votes

Cast

Against

Number of

Abstentions

Number of

BrokerNon-Votes

14,853,174

961,620 20,577

(2) Approval of the Companys amended and restated certificate of
incorporation to effect a reverse stock split of the Companys
common stock, at a ratio of one new share for every fourteen
shares outstanding.

Votes

Cast For

Votes

Cast

Against

Number of

Abstentions

Number of

BrokerNon-Votes

14,319,734

1,501,770 13,867

(3) Approval of an amendment to the Companys amended and restated
certificate of incorporation to change the name of the Company to
KalVista Pharmaceuticals, Inc.

Votes

Cast For

Votes

Cast

Against

Number of

Abstentions

Number of

BrokerNon-Votes

14,936,328

843,131 55,912

(4) Approval to adjourn the special meeting, if necessary, if a
quorum was present, to solicit additional proxies if there were
not sufficient votes in favor of the proposals set forth in
(1)through (3)above.

Votes

Cast For

Votes

Cast

Against

Number of

Abstentions

Number of

BrokerNon-Votes

14,988,281

635,931 211,159


About CARBYLAN THERAPEUTICS, INC. (NASDAQ:CBYL)

Carbylan Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of combination therapies. It focuses on the development of Hydros-TA, its intra-articular (IA) injectable product candidate to treat pain associated with osteoarthritis (OA) of the knee. Hydros-TA delivers both rapid pain relief with a low dose corticosteroid triamcinolone acetonide (TA) and sustained pain relief from its hyaluronic acid viscosupplement. Its Hydros-TA is a combination IA product, designed to provide both rapid and sustained pain relief with a single six milliliters intra-articular injection consists of over 52 milligrams of bacterially derived HA and over 10 milligrams of TA. Its first Phase III clinical trial of Hydros-TA, COR1.1, was a multi-center, international, randomized, double-blind, three-arm trial. Its Phase IIb clinical trial of Hydros-TA, COR1.0, was a multicenter, randomized, double-blind feasibility study.

CARBYLAN THERAPEUTICS, INC. (NASDAQ:CBYL) Recent Trading Information

CARBYLAN THERAPEUTICS, INC. (NASDAQ:CBYL) closed its last trading session down -0.003 at 0.667 with 3,286,386 shares trading hands.

An ad to help with our costs